Key facts
- Sentinal4D’s last known valuation is $6.0M (Jan 2025).
- It has raised $1.3M; the latest was Seed Round ($1.2M) in Jan 2025.
- Notable investors include Arben Ventures, Twin Path Ventures, Cancer Research Horizons, Cancer Tech Accelerator, Capital Research UK — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Sentinal4D
- ·The full record, as it builds
Funding rounds
No funding rounds for Sentinal4D are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sentinal4D
Developer of a biotechnology company pioneering 3D cell-based drug screening using advanced microscopy and deep learning. The company develops AI-powered platforms that analyse the shape and structure of thousands of single cells in 3D to uncover how drugs affect cellular behaviour., it generates interpretable morphological profiles, it helps pharmaceutical partners understand drug mechanisms, detect off-target effects, and prioritise promising therapies earlier in the pipeline, enabling patients battling cancer, neurodegenerative diseases, and chronic inflammatory syndromes to receive personalized therapeutics.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2022
- Employees
- 5
- Website
- sentinal4d.com/
- Ownership
- Privately Held (backing)
Sentinal4D doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sentinal4D shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sentinal4D in its N-PORT filings yet. We sweep new filings monthly.